MiniMed Group (MMED) total liabilities
MiniMed Group (MMED) had total liabilities of $1.02B at the end of fiscal 2026 (April 30, 2026). That is 17.1% higher than the $870.00M of fiscal 2025. Figures as of 19 Nov 2026, 03:14 UTC, from Yahoo Finance.
Key facts
- Total liabilities, fiscal 2026
- $1.02B
- Change on fiscal 2025
- +17.1%
- Highest on record
- $1.02Bfiscal 2026
- Lowest on record
- $646.00Mfiscal 2024
- Fiscal years on record
- 32024–2026
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
MiniMed Group total liabilities, in more detail
Across the 3 fiscal years on record (2024–2026), the highest was $1.02B in fiscal 2026 and the lowest $646.00M in fiscal 2024.
Total liabilities by fiscal year
MiniMed Group total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2026 | $1.02B | 17.1% up | |
| 2025 | $870.00M | 34.7% up | |
| 2024 | $646.00M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Ionis Pharmaceuticals IONS | $3.03B | 2025 |
| Dianthus Therapeutics DNTH | $37.52M | 2025 |
| MiniMed Group MMED | $1.02B | 2026 |
| Adaptive Biotechnologies ADPT | $287.74M | 2025 |
| Heartflow HTFL | $58.81M | 2025 |
| CRISPR Therapeutics CRSP | $343.43M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
MiniMed Group, figure by figure
- MiniMed Group market cap
- MiniMed Group revenue
- MiniMed Group earnings
- MiniMed Group earnings per share (EPS)
- MiniMed Group P/E ratio
- MiniMed Group P/S ratio
- MiniMed Group P/B ratio
- MiniMed Group free cash flow
- MiniMed Group operating margin
- MiniMed Group dividend
- MiniMed Group shares outstanding
- MiniMed Group total debt
- MiniMed Group cash on hand
- MiniMed Group total assets
- MiniMed Group net assets (shareholders' equity)
- MiniMed Group return on equity (ROE)
- MiniMed Group return on invested capital (ROIC)
MiniMed Group (MMED) overview: price, valuation and scorecardAll health care companies by market value
MiniMed Group total liabilities: questions and answers
How large are MiniMed Group's total liabilities?
MiniMed Group (MMED) had total liabilities of $1.02B at the end of fiscal 2026 (April 30, 2026). That is 17.1% higher than the $870.00M of fiscal 2025.
What are the highest and lowest total liabilities figures on record for MiniMed Group?
Across the 3 fiscal years on record (2024–2026), the highest was $1.02B in fiscal 2026 and the lowest $646.00M in fiscal 2024.
How is MiniMed Group's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For MiniMed Group it is on record here for 3 fiscal years, 2024 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “MiniMed Group (MMED) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/MMED/total-liabilities
Underlying data: Yahoo Finance.